# Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema

> **NCT01787669** · PHASE2 · COMPLETED · sponsor: **University of Sydney** · enrollment: 19 (actual)

## Conditions studied

- Diabetes
- Diabetic Macular Oedema
- Diabetic Macular Edema
- Diabetic Retinopathy

## Interventions

- **DRUG:** Avastin (Bevacizumab)
- **DRUG:** Ozurdex (dexamethasone)

## Key facts

- **NCT ID:** NCT01787669
- **Lead sponsor:** University of Sydney
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2017-01
- **Final completion:** 2017-10
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2018-11-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01787669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01787669, "Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01787669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*